2197.HK HKSE
Clover Biopharmaceuticals, Ltd.
1W: -13.1%
1M: -12.2%
3M: +4.7%
YTD: -22.8%
1Y: +179.7%
3Y: +84.5%
HK$1.85 ($0.24)
+0.07 (+3.92%)
Weekly Expected Move ±8.9%
HK$1
HK$2
HK$2
HK$2
HK$2
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
-$288M
+60.4% ▲
Capital Expenditures
$2M
+82.3% ▲
5Y CAGR: -24.9%
Free Cash Flow
-$290M
+60.6% ▲
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$335M
+61.6% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$913M | -$6.0B | -$2.5B | -$139M | -$903M |
| Depreciation & Amort. | $6M | $25M | $60M | $75M | $0 |
| Stock-Based Comp. | $0 | $125M | $95M | $54M | $16M |
| Change in Working Capital | $752M | $1.1B | $57M | $40M | -$66M |
| Other Non-Cash Items | $633M | $3.8B | $549M | -$758M | $664M |
| Operating Cash Flow | $477M | -$918M | -$1.7B | -$728M | -$288M |
| — Investing Activities — | |||||
| Capital Expenditures | -$114M | -$80M | -$106M | -$7M | $0 |
| Acquisitions (Net) | $0 | $21M | $0 | $0 | $0 |
| Investment Purchases | -$280M | -$30M | -$14M | $0 | $0 |
| Investment Sales | $0 | $222M | $80M | $3M | $5M |
| Other Investing | $0 | -$21M | $2M | -$2M | -$2M |
| Investing Cash Flow | -$394M | $112M | -$38M | -$6M | $3M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$4M | -$15M | $294M | -$29M | -$234M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | -$101M | $0 | $0 | $0 |
| Other Financing | -$10M | -$63M | -$264M | -$114M | $183M |
| Financing Cash Flow | $317M | $3.1B | $483M | -$142M | -$51M |
| Net Change in Cash | $367M | $2.3B | -$1.2B | -$872M | -$335M |
| Cash End of Period | $516M | $2.8B | $1.6B | $736M | $401M |
| Free Cash Flow | $363M | -$998M | -$1.8B | -$737M | -$290M |